Mosunetuzumab for relapsed or refractory B-cell follicular lymphoma – third-line and greater

featured image
Interventions: Mosunetuzumab (BTCT4465A)
Indications: Follicular lymphoma
Year: 2021

Mosunetuzumab is in clinical development for the treatment of patients with relapsed or refractory B-cell follicular lymphoma (FL). FL is a type of slow growing blood cancer that affects white blood cells. In FL, the affected white blood cells start to multiply in an abnormal way and begin to aggregate in certain parts of the body such as the lymph nodes. A recurrence of lymphoma after going into complete remission is known as a relapse. Lymphoma that is unresponsive to therapy it is called refractory lymphoma. The condition can become more difficult to treat if it is relapsed or refractory, as treatment options are limited.
Mosunetuzumab is a medicinal product administered intravenously. It works by binding to proteins called CD3 and CD20 expressed on the surface of B-cells and T-cells. This then reduces the growth and expression of cancer causing CD20 on B-cells. If licensed, mosunetuzumab will offer an additional treatment option for adults with relapsed or refractory B-cell follicular lymphoma (FL).